Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by ImmunoPrecise Antibodies IPA’s Subsidiary BioStrand Unveils Use Case for Solving the Information Integration Dilemma (IID) June 13, 2023 From ImmunoPrecise Antibodies Via Business Wire Tickers IPA IPA Releases New HYFT-Powered In Silico Humanization Platform, Aims to Disrupt the Transgenic Animal Model Market June 06, 2023 From ImmunoPrecise Antibodies Via Business Wire Tickers IPA IPA's Subsidiary, BioStrand, Solves the Information Integration Dilemma (IID) for Systems Biology May 30, 2023 From ImmunoPrecise Antibodies Via Business Wire Tickers IPA IPA to Present at Jefferies Healthcare Conference 2023 May 17, 2023 From ImmunoPrecise Antibodies Via Business Wire Tickers IPA ImmunoPrecise’s Subsidiary Talem Enters into Exclusive Research Collaboration and License Option Agreement with Astellas March 30, 2023 From ImmunoPrecise Antibodies Via Business Wire Tickers IPA European Patent Office to Grant BioKey’s Patent Application for Foundational HYFT® Technology March 27, 2023 From ImmunoPrecise Antibodies Via Business Wire Tickers IPA ImmunoPrecise Presents Novel T-Cell Engaging Bispecific Antibodies Addressing a Unique Oncological Target, Tropomyosin Receptor Kinase B, Associated with Poor Prognosis and Survival Rates March 23, 2023 From ImmunoPrecise Antibodies Via Business Wire Tickers IPA ImmunoPrecise Antibodies’ Subsidiary Talem Therapeutics Announces a Multi-Target AI-Driven Antibody Discovery Collaboration with Libera Bio March 15, 2023 From ImmunoPrecise Antibodies Via Business Wire Tickers IPA IPA’s Subsidiary BioStrand Completes Integration of 20 Million Proprietary Structural HYFTs™ and Accelerates in Silico Drug Discovery Developments December 08, 2022 From ImmunoPrecise Antibodies Via Business Wire Tickers IPA IPA’s Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies November 30, 2022 From ImmunoPrecise Antibodies Via Business Wire Tickers BCTX BCTXW IPA TSX:BCT NIAID Confirms IPA’s PolyTope TATX-03 Neutralizing Activity Against the Currently Spreading SARS-CoV-2 Variant BA.2.75 September 14, 2022 From ImmunoPrecise Antibodies Via Business Wire Tickers IPA TSX-V:IPA Live Virus Assays at Ludwig-Maximilians-Universität München Confirm PolyTope’s Efficacy Against SARS-CoV-2 Variants Including BA.5 August 29, 2022 From ImmunoPrecise Antibodies Via Business Wire Tickers IPA TSX-V:IPA IPA’s Advanced PolyTope® TATX-03, a Multi-Antibody Cocktail, Potently Prevents In Vitro Infection of Cells by the Currently Dominant Omicron Sublineage BA.2, in Addition to all Other Variants of Concern April 20, 2022 From ImmunoPrecise Antibodies Via Business Wire Tickers IPA TSX-V:IPA Histopathology Data of Preclinical Repeated Dose Toxicity Study and ex vivo Human Tissue Cross-Reactivity (TCR) Analysis Support Safety of IPA’s PolyTope® TATX-03, a Synergistic Antibody Cocktail against SARS‑CoV‑2 July 12, 2022 From ImmunoPrecise Antibodies Via Business Wire Tickers IPA TSX-V:IPA IPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue – Adding Artificial Intelligence-Driven Analytics to its Antibody Discovery Capabilities and Offerings April 14, 2022 From ImmunoPrecise Antibodies Via Business Wire Tickers IPA TSX-V:IPA IPA’s Subsidiary BioStrand Secures Second VLAIO Research Grant May 09, 2022 From ImmunoPrecise Antibodies Via Business Wire Tickers IPA TSX-V:IPA IPA Announces Agreement to Acquire BioStrand BV – Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with Advanced Artificial Intelligence March 29, 2022 From ImmunoPrecise Antibodies Via Business Wire Tickers IPA Eurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform June 22, 2021 From ImmunoPrecise Antibodies Via Business Wire Tickers IPA Histopathology Preclinical Data from ImmunoPrecise’s Polytope™ Program Confirms Lung Inflammation Reduction June 17, 2021 From ImmunoPrecise Antibodies Via Business Wire Tickers IPA Preclinical Data from ImmunoPrecise’s Drug Pipeline to be Presented During the BIO International Partnering Event June 15, 2021 From ImmunoPrecise Antibodies Via Business Wire Tickers IPA ImmunoPrecise Announces Appointment of Dr. Ilse Roodink to the Role of Chief Scientific Officer and Resignation of Dr. Yasmina Abdiche June 02, 2021 From ImmunoPrecise Antibodies Via Business Wire Tickers IPA ImmunoPrecise Names Dr. Dion Neame to Strategic Advisory Board May 25, 2021 From ImmunoPrecise Antibodies Via Business Wire Tickers IPA ImmunoPrecise Moves SARS-CoV-2 PolyTope™ Cocktail Program’s Path Toward IND Filing May 20, 2021 From ImmunoPrecise Antibodies Via Business Wire Tickers IPA ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer’s Disease April 08, 2021 From ImmunoPrecise Antibodies Via Business Wire Tickers IPA Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.